NEW YORK (GenomeWeb News) – Biopharmaceutical firm Berg and the US Department of Defense today announced an agreement to discover biomarkers for prostate cancer and to develop more effective treatments for the disease.

The deal is in the form of a Cooperative Research and Development agreement with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.